Floatz logo

ALECTINIB

Recurrent Adult Soft Tissue Sarcoma

OHSU Knight Cancer InstituteSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

103 Active assets in the Recurrent Adult Soft Tissue Sarcoma cohort.

Asset / SponsorPhaseRating
Palbociclib
Brown University
Phase 2BB
FILGRASTIM
University of California, Irvine
Phase 3BB
Inno-206
GI Innovation, Inc.
Phase 3BB
Eloxatin
OHSU Knight Cancer Institute
Phase 2BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

ALECTINIB is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Drug MonitoringDormant
BB
Indicative ·
65 / 100
View asset →
Anaplastic Lymphoma Kinase Gene MutationDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →